Aldeyra Therapeutics. has been granted a patent for pharmaceutical compositions containing a quinoline compound, aimed at treating various conditions, including inflammatory and respiratory diseases, organ diseases, and viral infections, as well as related conditions like acute respiratory distress syndrome. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical compositions for treating various diseases and conditions
The granted patent US12064516B2 outlines a pharmaceutical composition that includes a compound referred to as I-1, which can be utilized in various forms, including as a spray-dried solid. The composition may contain compound I-1 or its pharmaceutically acceptable salts, combined with a copolymer of methacrylate and acrylate. Specific formulations are detailed, indicating that for every 1 mg of compound I-1, approximately 0.9 mg to 3.6 mg of the copolymer is mixed in. The patent also specifies that the composition can be delivered in capsule or tablet form, with dosages ranging from 5 mg to 500 mg of compound I-1.
Additionally, the patent provides information on the pharmacokinetic properties of the pharmaceutical composition when administered orally to human subjects. It specifies various daily doses, including 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 700 mg, and 1200 mg, and outlines expected pharmacokinetic results. The half-life (t1/2) of the compound in human subjects is noted to be between 3 to 8 hours, with specific dosing regimens such as 50 mg BID, 150 mg BID, 350 mg BID, or 600 mg BID also mentioned. Overall, the claims detail the composition's formulation, dosage, and pharmacokinetic characteristics, providing a comprehensive overview of the potential applications of compound I-1 in pharmaceutical settings.
To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
